https://doi.org/10.4081/hmr.v1i8.277

Imatinib – an overview

Vol. 1 No. 8: New Drugs in Hematology, Bologna, October 9-11, 2005
Published: May 29, 2009
Abstract Views: 437
PDF: 4343
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

MVN Deininger
support@pagepress.org
Historical perspective and chemical development The potential of Abl kinase inhibitors for the treatment of Abl-related leukemias was suggested as early as 1989.1 Several tyrphostins, a series of compounds derived from the erbstatin, an inhibitor of the epidermal growth factor receptor were shown to be potent and rather specific inhibitors of Bcr-Abl, with biological activity in cell lines derived from patients with chronic myeloid leukemia (CML).2 Tyrphostins were however not developed clinically. Imatinib, the first clinically viable Abl kinase inhibitor, is the result of a medicinal chemistry project initiated by Ciba Geigy (now Novartis) in the early 1990s, with protein kinase C as the initial target. During this project, a 2-phenylaminopyrimidine derivative was identified as the lead compound.3,4

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Deininger, M. (2009). Imatinib – an overview. Hematology Meeting Reports (formerly Haematologica Reports), 1(8). https://doi.org/10.4081/hmr.v1i8.277
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).